CYCLERION THERAPEUTICS INC (CYCN) Fundamental Analysis & Valuation

NASDAQ:CYCN • US23255M2044

1.49 USD
+0.08 (+5.67%)
Last: Mar 9, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CYCN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

CYCN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. While CYCN seems to be doing ok healthwise, there are quite some concerns on its profitability. CYCN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. CYCN Profitability Analysis

1.1 Basic Checks

  • In the past year CYCN has reported negative net income.
  • CYCN had a negative operating cash flow in the past year.
  • CYCN had negative earnings in each of the past 5 years.
  • CYCN had a negative operating cash flow in each of the past 5 years.
CYCN Yearly Net Income VS EBIT VS OCF VS FCFCYCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of CYCN (-21.11%) is better than 75.14% of its industry peers.
  • CYCN has a Return On Equity of -23.06%. This is in the better half of the industry: CYCN outperforms 79.96% of its industry peers.
Industry RankSector Rank
ROA -21.11%
ROE -23.06%
ROIC N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
CYCN Yearly ROA, ROE, ROICCYCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

  • CYCN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCN Yearly Profit, Operating, Gross MarginsCYCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CYCN Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CYCN has been increased compared to 1 year ago.
  • The number of shares outstanding for CYCN has been increased compared to 5 years ago.
  • There is no outstanding debt for CYCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYCN Yearly Shares OutstandingCYCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
CYCN Yearly Total Debt VS Total AssetsCYCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -32.71, we must say that CYCN is in the distress zone and has some risk of bankruptcy.
  • CYCN has a worse Altman-Z score (-32.71) than 89.40% of its industry peers.
  • CYCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.71
ROIC/WACCN/A
WACCN/A
CYCN Yearly LT Debt VS Equity VS FCFCYCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

  • CYCN has a Current Ratio of 5.78. This indicates that CYCN is financially healthy and has no problem in meeting its short term obligations.
  • CYCN has a Current ratio of 5.78. This is in the better half of the industry: CYCN outperforms 60.69% of its industry peers.
  • A Quick Ratio of 5.78 indicates that CYCN has no problem at all paying its short term obligations.
  • The Quick ratio of CYCN (5.78) is better than 62.04% of its industry peers.
Industry RankSector Rank
Current Ratio 5.78
Quick Ratio 5.78
CYCN Yearly Current Assets VS Current LiabilitesCYCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CYCN Growth Analysis

3.1 Past

  • CYCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.04%, which is quite impressive.
  • The Revenue for CYCN have been decreasing by -15.01% on average. This is quite bad
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.73%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%353.61%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.45% on average over the next years. This is quite good.
  • CYCN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y-12.58%
EPS Next 2Y11.53%
EPS Next 3Y9.45%
EPS Next 5YN/A
Revenue Next Year-43.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CYCN Yearly Revenue VS EstimatesCYCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 2025 1M 2M 3M 4M
CYCN Yearly EPS VS EstimatesCYCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2025 2026 2027 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. CYCN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CYCN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCN Price Earnings VS Forward Price EarningsCYCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCN Per share dataCYCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.53%
EPS Next 3Y9.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYCN Dividend Analysis

5.1 Amount

  • No dividends for CYCN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYCN Fundamentals: All Metrics, Ratios and Statistics

CYCLERION THERAPEUTICS INC

NASDAQ:CYCN (3/9/2026, 8:00:01 PM)

1.49

+0.08 (+5.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-04
Inst Owners8.03%
Inst Owner Change9.02%
Ins Owners18.74%
Ins Owner Change0%
Market Cap5.86M
Revenue(TTM)2.85M
Net Income(TTM)-2.20M
Analysts82.86
Price Target8.16 (447.65%)
Short Float %4.4%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)100%
PT rev (3m)100%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.05
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.73
BVpS2.43
TBVpS2.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.11%
ROE -23.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.78
Quick Ratio 5.78
Altman-Z -32.71
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.73%
EPS Next Y-12.58%
EPS Next 2Y11.53%
EPS Next 3Y9.45%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%353.61%
Revenue Next Year-43.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y62.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y94.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.86%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLERION THERAPEUTICS INC / CYCN FAQ

What is the ChartMill fundamental rating of CYCLERION THERAPEUTICS INC (CYCN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYCN.


Can you provide the valuation status for CYCLERION THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CYCLERION THERAPEUTICS INC (CYCN). This can be considered as Overvalued.


How profitable is CYCLERION THERAPEUTICS INC (CYCN) stock?

CYCLERION THERAPEUTICS INC (CYCN) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CYCLERION THERAPEUTICS INC?

The Earnings per Share (EPS) of CYCLERION THERAPEUTICS INC (CYCN) is expected to decline by -12.58% in the next year.